iRhythm announces publication of AVALON study of Zio LTCM

iRhythm (IRTC) Technologies announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries, AVALON, in the American Journal of Managed Care reinforcing the clinical superiority of the Zio long-term continuous monitoring, LTCM, service. Building on findings from the CAMELOT study – published in the American Heart Journal – which demonstrated the clinical superiority of the Zio LTCM service among a Medicare population, the AVALON study evaluated a younger, commercially insured population. Like CAMELOT, the AVALON data demonstrated that the Zio LTCM service was associated with the highest diagnostic yield compared to other studied ambulatory cardiac monitoring modalities and all other LTCM services, and a lower likelihood of repeat testing compared to all other LTCM services. In AVALON, the investigators also found that the Zio LTCM service was associated with a lower likelihood of cardiovascular events compared to other studied ACM modalities and all other LTCM services, and was associated with a faster time to diagnoses, reduced health care resource utilization, and lower total health care costs during the follow-up period after monitoring – in the largest and most comprehensive real-world study of ambulatory cardiac monitoring among commercially insured adults.